Nonalcoholic Steatohepatitis (NASH) Clinical Trials

A listing of Nonalcoholic Steatohepatitis (NASH) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 111 clinical trials
Featured trial
TREATMENT OF LIVER FIBROSIS IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)

NASH IS LIVER INFLAMMATION AND DAMAGE CAUSED BY A BUILDUP OF FAT IN THE LIVER.  

  • 142 views
  • 03 Oct, 2019
  • 1 location
Featured trial
Ascend-Nash: A Phase 2b, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Crv431 In Adult Subjects With Nonalcoholic Steatohepatitis And Advanced Liver Fibrosis

biopsy-proven nonalcoholic steatohepatitis (NASH) and stage 2 liver fibrosis (F2) / stage 3 liver fibrosis (F3).Exploratory:To validate the use of a composite NASH multi-omics AI-POWR™ biomarker

  • 0 views
  • 29 Sep, 2022
  • 1 location
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

  • 1167 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

  • 446 views
  • 25 Mar, 2021
  • 1 location
Featured trial
TARGET-NASH: A 5-year longitudinal observational study of patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis

TARGET-NASH: A 5-year longitudinal observational study of patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis

  • 426 views
  • 23 Nov, 2020
  • 1 location
  • 70 views
  • 04 Oct, 2022
  • 105 locations
Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis.

This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI

  • 132 views
  • 21 Oct, 2022
  • 130 locations
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatohepatitis (NASH).

  • 0 views
  • 04 Oct, 2022
  • 1 location
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (SYNERGY-NASH)

The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).

  • 354 views
  • 22 Oct, 2022
  • 110 locations
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults With Compensated Cirrhosis From Nonalcoholic Steatohepatitis (NASH)

The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty

  • 1 views
  • 28 Oct, 2022
  • 58 locations